TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07570758: A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Sponsor: ERX Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 80 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$6,108,800

Rescue Site Savings

+$4,017,200

Unlock Full NCT07570758 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07570758 Rescue Dossier →